Evidence map›Paper›PMID 40372494›Full record

ArticleAnnals of hematology2025

Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma.

Julius C Enssle, Tonio Brinkschmidt, Ralf Dürrwald, Sebastian Wolf, David Zurmeyer, Björn Steffen, Evelyn Ullrich, Thomas Oellerich, Hubert Serve, Ivana von Metzler

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Julius C EnssleDepartment of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt Am Main, Germany.
Tonio BrinkschmidtDepartment of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt Am Main, Germany.
Ralf DürrwaldInfluenza National Reference Center, Robert Koch Institute, Berlin, Germany.
Sebastian WolfDepartment of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt Am Main, Germany.
David ZurmeyerDepartment of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt Am Main, Germany.
Björn SteffenDepartment of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt Am Main, Germany.
Evelyn UllrichFrankfurt Cancer Institute (FCI), Frankfurt Am Main, Germany.
Thomas OellerichDepartment of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt Am Main, Germany.
Hubert ServeDepartment of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt Am Main, Germany.
Ivana von MetzlerDepartment of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt Am Main, Germany. metzler@med.uni-frankfurt.de.

Funding

Else-Kröner-Fresenius Foundation 2023_EKEA.193
6 · The paper itself

Abstract

Seasonal Influenza A/B vaccination is routinely administered in patients with Multiple Myeloma (MM) given their disease-and therapy-associated immunosuppression and risk of infection. Previous data show poor seroconversion rates after one vaccination with an increase to ~ 60% after boosting while the impact of multiple lines of therapy remains unclear. Accordingly, we performed a retrospective single-center study assessing immune responses after single or prime-boosting vaccination in 71 patients with MM treated at our institution during the 2019/20 season. Overall, 63.3% of patients with MM achieved sufficient responses after one or two Influenza A/B vaccinations. In patients receiving a prime-boost approach, significantly higher serological titers but no significant increase in responder rates were observed after the boost vaccination. Complete or very good partial remission and no immunoparesis were identified as independent predictors of sufficient serological response by multivariate regression analysis and responders were characterized by high CD19

Indexed as

Influenza A virusInfluenza B virusInfluenza, HumanInfluenza VaccinesMultiple MyelomaVaccinationAdultAgedAntibodies, ViralFemaleHumansImmunization, SecondaryMaleMiddle AgedRetrospective StudiesAntibodies, ViralInfluenza VaccinesInfluenza A/BMultiple myelomaSerological and immune cell responseVaccination

Identifiers

PMID40372494
PMCPMC12141375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.